Small-molecule prodrug

A small-molecule prodrug is a pharmacologically inactive or less active chemical derivative of a drug molecule that requires a spontaneous or enzymatic transformation within the body to release the active drug (Huttunen et al., Pharmacological Reviews, 2011). This design strategy is utilized to optimize the physicochemical, biopharmaceutical, or pharmacokinetic properties of a therapeutic agent, such as increasing water solubility, enhancing membrane permeability, or prolonging the half-life. Prodrugs are often engineered to overcome barriers like poor oral absorption or high first-pass metabolism (Rautio et al., Nature Reviews Drug Discovery, 2018). Upon administration, they are typically activated by specific enzymes such as esterases, amidases, or cytochrome P450 isoforms. While highly effective for improving drug delivery, the success of a prodrug depends on the predictable conversion to its active form, which can be influenced by patient-specific factors like genetics and organ function. This approach is widely used in various therapeutic areas, including oncology, cardiology, and infectious diseases, to optimize the delivery and efficacy of therapeutic agents.

Other names

ProdrugPro-drugLatentiated drugBioreversible derivative

Small-molecule prodrugs function by undergoing a chemical or enzymatic transformation (such as hydrolysis, oxidation, or reduction) to release the active pharmaceutical ingredient (API) at the desired site of action or systemically (Rautio et al., Nature Reviews Drug Discovery, 2008).